Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

2-DG protects mouse from DSS-induced inflammatory bowel disease

ABSTRACT: Anti-proinflammatory cytokine therapies against interleukin (IL)-6 and tumor necrosis factor (TNF)-a are major advances in treating inflammatory diseases. We found that 2-deoxy-D-glucose (2-DG), a simple monosaccharide, attenuated IL-6 responses by inhibiting N-linked glycosylation of the IL-6 receptor gp130. Aglyco forms of gp130 failed to bind IL-6 and to activate downstream signals. 2-DG completely inhibited dextran sodium sulfate-induced inflammatory bowel disease that was partially dependent on IL-6.

ORGANISM(S): Mus musculus

PROVIDER: GSE167598 | GEO | 2021/10/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

2-DG protects mouse from DSS-induced inflammatory bowel disease

Project description:2-DG protects mouse from DSS-induced inflammatory bowel disease

| PRJNA705115 | ENA

DG vs superficial gonorrhoeae comparisons

Project description:transcription profiles of two groups each containing 5 strains of Disseminated gonorrhoeae (DG) and Undisseminated (superficial) gonorrhoeae (UG) were compared. An additional set of comparisons was done between 4 strains from group one Disseminated gonorrhoeae (DG) and another 4 strains from the same group.

2012-06-15 | E-MEXP-3254 | biostudies-arrayexpress

Global gene expression in Head and neck squamous carcinoma (KB) cells treated with the combination of 2-DG + 6-AN followed by irradiation (2-Gy)

Project description:Whole genome expression profiling of head and neck squamous carcinoma (KB) cells comparing control untreated cells as well as irradited (2 Gy) alone cells with carcinoma cells treated with the combination of 2-DG and 6-AN followed by irradiation (2 Gy). Goal of this study was to study the global gene expression involved in radiosensitization of Head and neck squamous carcinoma (KB cells) treated with the combination of two metabolic modifers namely 2-deoxy-D-Glucose (2-DG) and 6-Aminonicotinamide (6-AN) followed by irradiation (2 Gy). This will enable us to understand the role of metabolic oxidative stress (MOS) involved in the radiosensitization of cancer cells and regulation between complex molecular circuits to develop better therapeutic approaches/ protection against oxidative damage.

2014-12-31 | GSE23989 | GEO

Effect of IL-17R in Paneth cells after DSS challenge

Project description:Mice with Paneth cell specific genetic ablation of IL-17 receptor and their WT littermates were treated with DSS (dextran sulfate sodium). Ileum tissue was used for RNA Sequencing.

2022-02-02 | E-MTAB-11380 | biostudies-arrayexpress

N2-heptynyl-dG sequencing

Project description:N2-heptynyl-dG sequencing in HEK293T cells

2024-06-15 | GSE261442 | GEO

Pharmacoproteomics of non-human primate cerebrospinal fluid after BACE inhibition

Project description:The protease BACE1 is a major drug target for Alzheimer’s disease, but chronic BACE1 inhibition is associated with non-progressive worsening that may be caused by modulation of unknown physiological BACE1 substrates. To identify in vivo-relevant BACE1 substrates we applied pharmacoproteomics to non-human-primate cerebrospinal fluid (CSF) after acute treatment with BACE inhibitors. Besides SEZ6, the strongest, dose-dependent reduction was observed for the pro-inflammatory cytokine receptor gp130/IL6ST, which we establish as a new in vivo BACE1 substrate. Gp130 was also reduced in human CSF from a clinical trial with a BACE inhibitor and in plasma of BACE1-deficient mice. Mechanistically, we demonstrate that BACE1 directly cleaves gp130, thereby attenuating membrane-bound gp130 and increasing soluble gp130 abundance and controlling gp130 function in neuronal IL-6 signaling and neuronal survival upon growth-factor withdrawal. In conclusion, BACE1 is a new modulator of gp130 function. The BACE1-cleaved, soluble gp130 may serve as a pharmacodynamic BACE1 activity marker to reduce the occurrence of side effects of chronic BACE1 inhibition in humans.

2023-02-23 | PXD035141 | Pride

Cell-autonomous hepatocyte-specific GP130 signalling alone is sufficient to trigger robust innate immune response in mice

Project description:Members of the IL-6 cytokine family contribute to inflammatory and regenerative processes. Engagement of the signalling receptor subunit gp130 is common to almost all members of the family. In the liver, all major cell types respond to IL-6, making it difficult to delineate cell type-specific effects of IL-6 type cytokines. We therefore generated mouse models for liver cell type-specific analysis of IL-6 signalling.

2021-08-20 | PXD020744 | Pride

N2-heptynyl-dG sequencing

Project description:N2-heptynyl-dG sequencing

| PRJNA1086954 | ENA

Microarray analysis of regulatory and inflammatory macrophages differentiated with glycolysis inhibitor

Project description:The gene expression patterns of macrophages were analyzed to understand how glycolysis inhibitor affects macrophage differentiation. Human monocytes derived from peripheral blood were cultured in vitro in the presence of macrophage colony-stimulating factor (M-CSF) to yield regulatory macrophages (M-Mφs), or M-CSF plus interferon-gamma to yield inflammatory macrophages (Mγ-Mφs). 2-deoxy-D-glucose (2-DG), a glycolysis inhibitor, was added during macrophage differentiation. Gene expression patterns of monocytes, M-Mφs and Mγ-Mφs diffrentiated with or without 2-DG were analyzed by microarray analysis.

2016-03-07 | GSE74182 | GEO

Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease

Project description:Background A large unmet therapeutic need exists in inflammatory bowel diseases (IBD). Inhibition of interleukin (IL)-6 appears to be effective, but the therapeutic benefit of a complete IL-6/IL-6R blockade is limited by profound immunosuppression. Evidence has emerged, that chronic pro-inflammatory activity of IL-6 is mainly mediated by trans-signalling via a complex of IL-6 bound to soluble IL-6R engaging the gp130 receptor without the need of membrane bound IL6R. We have developed a decoy protein, sgp130Fc, which exclusively blocks IL-6 pro-inflammatory trans-signalling and has shown efficacy in preclinical models of IBD, without signs of immunosuppression. Methods We present a 12-week, open label, prospective phase IIa trial (FUTURE) in 16 patients with active IBD treated with the trans-signalling inhibitor olamkicept (sgp130Fc) to assess molecular mechanisms, safety and effectiveness of IL-6 trans-signalling blockade in vivo. We performed in-depth molecular profiling at various time points before and after therapy induction to identify the mechanism of action of olamkicept. Results Olamkicept was well tolerated and induced clinical response in 44% and clinical remission in 19% of patients. Clinical effectiveness coincided with target inhibition (reduction of phosphorylated STAT3) and marked transcriptional changes in the inflamed mucosa. An olamkicept-specific transcriptional signature, distinguishable from remission signatures of anti-TNF (infliximab) or anti-integrin (vedolizumab) therapies was identified. Conclusion Our data suggest that blockade of IL-6 trans-signaling holds large promise for the therapy of IBD and should undergo full clinical development as a new immunoregulatory therapy of IBD.

2021-04-10 | GSE171770 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data